Ketamine vs Antidepressants

Patients comparing ketamine to standard antidepressants — SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin–norepinephrine reuptake inhibitors), and atypicals — usually want to know one thing: is ketamine better, and should I switch? The honest answer in 2026 Canadian clinical practice is that they are not direct substitutes. SSRIs and SNRIs remain first-line for major depressive disorder under CANMAT 2023 guidelines, work via slow monoamine receptor adaptation, take 4–6 weeks for clinical effect, and cost cents per day. Ketamine is a third-line option for treatment-resistant depression (CANMAT 2021), works via glutamate/NMDA-mediated synaptogenesis, produces antidepressant effects in 2–72 hours, and costs orders of magnitude more. The pivotal Spravato trials (Daly 2018, Popova 2019, Daly 2019, Wajs 2020) all explicitly tested ketamine + concurrent oral antidepressant — most evidence-supported ketamine protocols are augmentation, not replacement. And the ELEKT-D trial (Anand 2023, NEJM) found IV ketamine non-inferior to ECT in non-psychotic TRD, repositioning ketamine within the third-line treatment landscape. This article walks through the comparison honestly.

Key takeaways

• First-line for MDD remains SSRIs/SNRIs + psychotherapy (CANMAT 2023). Ketamine is third-line for treatment-resistant depression after failure of two or more adequate antidepressant trials.
• Mechanism is fundamentally different. SSRIs/SNRIs modulate monoamines (serotonin, norepinephrine) over weeks. Ketamine acts on glutamate via NMDA antagonism, producing rapid synaptogenesis within 24–72 hours.
• Onset is the headline difference. SSRIs/SNRIs: 4–6 weeks for clinical response. Ketamine: 2–72 hours after a single dose.
• Combination is the standard. Most ketamine pivotal trials (Daly 2018, Popova 2019 TRANSFORM-2, Wajs 2020 SUSTAIN-2) tested ketamine + concurrent oral antidepressant. Ketamine is generally augmentation, not replacement.
• Durability differs. SSRIs/SNRIs maintain effect via continuous daily dosing. Ketamine effects last days to weeks per dose; maintenance protocols extend benefit (Wilkinson 2017 integration psychotherapy data).
• Side-effect profiles differ. SSRIs/SNRIs: GI, sexual dysfunction, weight changes, discontinuation syndrome. Ketamine: transient dissociation, brief BP elevation, mild nausea — different acute pattern, no withdrawal syndrome at therapeutic doses, but ketamine has misuse potential.
• Cost asymmetry is large. SSRIs/SNRIs are pennies per day, covered by all provincial drug plans. Ketamine is hundreds to thousands per session, generally not covered (Spravato is the partial exception with private prior auth).

How they work — fundamentally different mechanisms

Antidepressants — slow monoamine modulation

SSRIs and SNRIs work by inhibiting reuptake of serotonin (and norepinephrine for SNRIs) in the synaptic cleft. The increased synaptic monoamine availability is detected immediately, but the clinical antidepressant effect requires weeks because it depends on downstream receptor adaptation, gene expression changes, and slow neuroplastic remodeling. Most patients require 4–6 weeks at therapeutic dose to assess whether a given antidepressant will work.

Atypical antidepressants (bupropion, mirtazapine, vortioxetine) act on different but related monoaminergic systems with similar 4–6 week onset patterns.

Ketamine — rapid glutamate-mediated synaptogenesis

Ketamine's antidepressant effect operates through a different system entirely. NMDA receptor antagonism on cortical GABAergic interneurons disinhibits glutamatergic neurons. The resulting glutamate surge activates AMPA receptors and triggers BDNF release and mTOR-pathway signalling, producing synaptogenesis — new dendritic spines forming within 24 to 72 hours of a dose (Aleksandrova et al., 2017; Lullau et al., 2023). This bypasses the slow monoamine adaptation pathway and produces clinical effects in hours rather than weeks.

For the full mechanism breakdown, see What Is Ketamine Therapy?.

Onset speed — the headline difference

The clinical implication: for severe acute depression with suicidal ideation, ketamine's rapid effect has acute safety value that antidepressants alone cannot match. This is why Grunebaum et al. 2018 (Am J Psychiatry) demonstrated rapid reduction in suicidal ideation with single-dose IV ketamine (PubMed) and why some U.S. jurisdictions have approved Spravato for adults with major depressive disorder with acute suicidal ideation alongside the TRD indication.

Evidence comparison in TRD

CANMAT 2023's MDD treatment hierarchy is consistent across most current Canadian and international guidelines:

• First-line MDD: SSRIs, SNRIs, bupropion, vortioxetine, agomelatine — typically with psychotherapy (CBT, IPT, behavioural activation).
• Inadequate response after one trial: switch within or across class, or augment (e.g., aripiprazole, brexpiprazole, lithium, T3).
• Treatment-resistant depression (failure of two or more adequate trials at therapeutic dose for ≥6 weeks each): IV ketamine (third-line per Swainson et al. 2021, CANMAT racemic ketamine task force); Spravato as a Health Canada-approved option in combination with oral antidepressant; ECT for severe TRD particularly with psychotic features.

The ELEKT-D answer

The single most important head-to-head trial is Anand et al. 2023 — ELEKT-D — a 403-patient randomized comparison of IV ketamine versus ECT for non-psychotic TRD, published in the New England Journal of Medicine. The primary outcome (≥50% reduction on a 16-item self-report depression measure) was met in 55.4% of the ketamine arm versus 41.2% of the ECT arm — non-inferiority demonstrated. ECT had more memory and musculoskeletal side effects; ketamine had more dissociation. Cognitive outcomes were better in the ketamine arm at end of treatment.

The honest interpretation: for non-psychotic TRD, IV ketamine is comparable to ECT — historically considered the most effective TRD treatment. Ketamine's role in third-line TRD is well-supported in 2026.

Spravato trials — combination is the design

The pivotal Spravato trials all tested esketamine + concurrent oral antidepressant versus placebo + oral antidepressant:

• Daly et al. 2018 (JAMA Psychiatry) — Phase 2 dose-response in TRD on stable SSRI/SNRI background.
• Popova et al. 2019 TRANSFORM-2 (Am J Psychiatry) — flexibly dosed esketamine + newly initiated oral antidepressant outperformed placebo + same oral antidepressant.
• Daly et al. 2019 SUSTAIN-1 (JAMA Psychiatry) — patients in remission on continued esketamine + oral antidepressant had longer time to relapse than those switched to placebo + oral antidepressant.
• Wajs et al. 2020 SUSTAIN-2 (J Clin Psychiatry) — long-term safety up to 1 year on combination.

The pattern matters: the evidence-based ketamine protocol for TRD is augmentation, not replacement. Most patients continuing antidepressants while doing ketamine are following the most-studied protocol, not deviating from it.

Durability differences

Antidepressants — continuous daily dosing maintains effect

SSRIs and SNRIs are taken daily indefinitely (or until clinical decision to taper). Continuous adherence is what maintains the effect. Discontinuation typically produces relapse within weeks to months for many patients, though a subset can taper off after sustained remission.

Ketamine — repeated dosing for sustained benefit

A single ketamine dose produces antidepressant effects lasting days to ~2 weeks. The acute course (4–8 sessions over 2–3 weeks for IV; 12 sessions over 8 weeks for Spravato) extends response into the weeks-to-months range. Maintenance dosing every 1–4 weeks (tapering as durability allows) further extends benefit. Wilkinson et al. 2017 (Psychotherapy and Psychosomatics) showed that adding cognitive-behavioural therapy after the acute course extended antidepressant durability — the rationale for KAP integration psychotherapy.

The honest framing: ketamine is not a one-shot fix. The most-studied protocol is acute course + maintenance + integration psychotherapy.

For the deeper dive, see How Many Ketamine Treatments Do I Need?.

Side-effect comparison

Each profile has trade-offs. For patients who have struggled with SSRI sexual side effects or weight gain, ketamine's profile is genuinely different. For patients sensitive to dissociation or with cardiovascular risk factors, ketamine has its own challenges.

For the full ketamine safety picture, see Ketamine Therapy Side Effects.

Cost and access

The honest cost framing: the financial barrier to entry for SSRIs/SNRIs is essentially zero in Canada; for ketamine it is meaningful unless you have private coverage for Spravato or a workers' compensation pathway. This shapes which patients realistically access ketamine.

For full Canadian pricing context, see Ketamine Therapy Cost in Canada and Insurance Coverage for Ketamine Therapy.

How to think about the decision

A practical framing for patients evaluating ketamine versus antidepressants:

Start (or stay) with SSRIs/SNRIs if:

• You have major depressive disorder for the first time, or have responded to antidepressants previously.
• You have not tried at least two adequate antidepressant trials at therapeutic dose for ≥6 weeks each.
• Your situation does not require rapid response (no acute suicidality, no urgent functional crisis).
• Cost or access is a meaningful barrier to specialty treatment.

Add ketamine (alongside continued antidepressant) if:

• You meet TRD criteria — failure of two or more adequate antidepressant trials.
• You are in acute crisis where rapid response matters (suicidality, severe acute depression).
• You have completed adequate psychotherapy and are still in significant depression.
• Cost is manageable (Spravato with private prior auth is often the most affordable pathway).

Consider ketamine instead of further antidepressant trials if:

• You have failed multiple adequate antidepressant trials including augmentation.
• You and your prescriber agree that further pharmacologic optimization is unlikely to help.
• ECT, ketamine, or other third-line options are the next reasonable step.

Most patients on ketamine continue their existing antidepressant. The pivotal trials were designed that way, and CANMAT positioning supports that pattern. Ketamine is rarely framed as antidepressant replacement — it is augmentation, rescue, or third-line.

Frequently asked questions

Is ketamine better than antidepressants? Not for most patients with first-episode MDD — antidepressants + psychotherapy remain first-line per CANMAT 2023. For TRD specifically, ketamine has comparable evidence to ECT (ELEKT-D 2023) and is third-line under CANMAT 2021. The honest answer: better depends on which depression, which patient, and which prior treatments.

Can I stop my SSRI and switch to ketamine? Generally not recommended. The pivotal Spravato trials specifically tested ketamine + concurrent oral antidepressant. Discontinuing your antidepressant is a clinical decision with your prescriber; do not stop abruptly given discontinuation syndrome risk.

How fast does ketamine work compared to my SSRI? Ketamine produces antidepressant effects within 2–72 hours of a single dose. SSRIs typically require 4–6 weeks for clinical response.

Will ketamine replace my antidepressant? Probably not. The most-studied protocol is ketamine + concurrent oral antidepressant. A subset of patients eventually taper off antidepressants while maintaining ketamine response, but this is a clinical decision over time, not a starting plan.

What if my antidepressant has caused sexual side effects or weight gain? This is a common reason to consider ketamine alongside or as a transition strategy. Discuss with your prescriber. Some patients work with their psychiatrist to optimize the antidepressant dose or switch class while pursuing ketamine.

Are antidepressants and ketamine safe together? Generally yes. SSRIs and SNRIs are routinely combined with ketamine in pivotal trials. MAOIs are typically excluded due to theoretical hypertensive crisis risk. High-dose benzodiazepines may attenuate ketamine's antidepressant effect (Andrashko 2020). Discuss your medication list at intake.

What about ECT — how does ketamine compare? ELEKT-D (Anand 2023, NEJM) found IV ketamine non-inferior to ECT for non-psychotic TRD on the primary outcome. ECT remains preferred for severe TRD with psychotic features or when rapid inpatient response is needed; ketamine is often the more accessible outpatient option. See Ketamine Therapy for Treatment-Resistant Depression (deep dive).

What if cost is a barrier? Most patients cannot afford off-label generic ketamine without insurance. Spravato is the form most likely to have private prior-auth coverage in Canada. Workers' compensation pathways apply for compensable injuries. The Edmonton Misericordia public ketamine program is the only AHCIP-covered psychiatric ketamine option in Canada. See Ketamine Therapy in Edmonton and Insurance Coverage for Ketamine Therapy.

Does ATMA CENA offer both ketamine and antidepressant management? ATMA CENA's intake call coordinates with your existing prescribing physician (GP or psychiatrist) for antidepressant management; ATMA CENA provides KAP medical oversight and the dosing infrastructure. The coordinated care model is built around this coordinated approach.

Will I become dependent on ketamine? At supervised therapeutic doses with no take-home dispensing, dependence has not emerged as a clinical issue in published trials. Ketamine has misuse potential — supervised in-clinic delivery is the mitigation. SSRIs and SNRIs do not produce dependence in the same sense, but many patients experience meaningful discontinuation syndrome on abrupt stopping.

Sources

1. ATMA CENA — coordinated care: https://psychedelic.healthcare/find-care
2. Aleksandrova LR, et al. (2017). Antidepressant mechanisms of ketamine. Can J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/28234212/
3. Lullau APM, et al. (2023). Antidepressant mechanisms of ketamine. Front Neurosci. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1223145/full
4. Swainson J, et al. (2021). CANMAT racemic ketamine task force recommendations. Can J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/33174760/
5. Daly EJ, et al. (2018). Phase 2 dose-response esketamine in TRD. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29282469/
6. Popova V, et al. (2019). TRANSFORM-2 — esketamine + new oral antidepressant in TRD. Am J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/31109201/
7. Daly EJ, et al. (2019). SUSTAIN-1 — Spravato maintenance of efficacy. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/31268507/
8. Wajs E, et al. (2020). SUSTAIN-2 — Spravato long-term safety. J Clin Psychiatry. https://pubmed.ncbi.nlm.nih.gov/32316080/
9. Anand A, et al. (2023). Ketamine versus ECT for nonpsychotic TRD: ELEKT-D. N Engl J Med. https://pubmed.ncbi.nlm.nih.gov/37224135/
10. Grunebaum MF, et al. (2018). Ketamine for rapid reduction of suicidal thoughts in MDD. Am J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/29202575/
11. Andrashko V, et al. (2020). Benzodiazepine attenuation of ketamine antidepressant effect. Front Psychiatry. https://pubmed.ncbi.nlm.nih.gov/33384625/

Related articles in this cluster

• Ketamine Therapy in Canada
• What Is Ketamine Therapy?
• Ketamine Therapy for Depression
• Ketamine Therapy for Treatment-Resistant Depression (deep dive)
• Ketamine vs Spravato
• Ketamine vs Psilocybin Therapy
• How Many Ketamine Treatments Do I Need?
• Ketamine Therapy Side Effects
• Insurance Coverage for Ketamine Therapy
• Find care near you

Last updated: 2026-05-06